Accelerate Diagnostics (AXDX)
(Delayed Data from NSDQ)
$1.78 USD
+0.06 (3.49%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $1.75 -0.03 (-1.69%) 7:58 PM ET
2-Buy of 5 2
F Value A Growth B Momentum C VGM
Balance Sheet
Fiscal Year End for Accelerate Diagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 13 | 46 | 64 | 68 | 108 |
Receivables | 3 | 2 | 2 | 2 | 3 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 5 | 5 | 9 | 8 |
Other Current Assets | 5 | 3 | 2 | 3 | 2 |
Total Current Assets | 24 | 56 | 73 | 82 | 122 |
Net Property & Equipment | 2 | 3 | 5 | 6 | 8 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 4 | 2 | 2 | 1 |
Total Assets | 31 | 65 | 83 | 93 | 134 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 1 | 56 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 2 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 1 | 1 | 0 | 0 | 0 |
Accrued Expenses | 3 | 3 | 4 | 4 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 1 | 0 | 0 | 0 |
Total Current Liabilities | 12 | 67 | 7 | 7 | 8 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 0 | 0 | 0 | 0 |
Convertible Debt | 36 | 0 | 108 | 141 | 130 |
Long-Term Debt | 0 | 17 | 0 | 5 | 0 |
Non-Current Capital Leases | 0 | 1 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 2 | 1 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 51 | 87 | 118 | 156 | 142 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 695 | 630 | 581 | 475 | 452 |
Retained Earnings | -669 | -607 | -571 | -493 | -415 |
Other Equity | -1 | 0 | 0 | 0 | 0 |
Treasury Stock | 45 | 45 | 45 | 45 | 45 |
Total Shareholder's Equity | -20 | -22 | -35 | -63 | -7 |
Total Liabilities & Shareholder's Equity | 31 | 65 | 83 | 93 | 134 |
Total Common Equity | -20 | -22 | -35 | -63 | -7 |
Shares Outstanding | 14.57 | 9.91 | 6.10 | 5.90 | 5.40 |
Book Value Per Share | -1.37 | -2.25 | -5.75 | -10.65 | -1.37 |
Fiscal Year End for Accelerate Diagnostics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 10 | 16 | 13 | 21 | 31 |
Receivables | 2 | 2 | 3 | 3 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 3 | 3 | 4 | 5 |
Other Current Assets | 2 | 3 | 5 | 5 | 4 |
Total Current Assets | 17 | 24 | 24 | 32 | 42 |
Net Property & Equipment | 3 | 3 | 2 | 3 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 2 | 2 | 3 | 3 | 3 |
Total Assets | 23 | 31 | 31 | 39 | 50 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 1 | 1 | 1 | 1 |
Accounts Payable | 4 | 5 | 5 | 5 | 4 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 1 | 1 | 0 | 1 |
Accrued Expenses | 3 | 4 | 3 | 5 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 6 | 4 | 2 | 26 | 43 |
Total Current Liabilities | 13 | 16 | 12 | 38 | 54 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 1 | 0 |
Convertible Debt | 41 | 38 | 36 | 33 | 32 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 2 | 1 | 1 | 1 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 58 | 57 | 51 | 74 | 89 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 705 | 703 | 695 | 666 | 664 |
Retained Earnings | -695 | -683 | -669 | -656 | -657 |
Other Equity | 0 | -1 | -1 | 0 | -1 |
Treasury Stock | 45 | 45 | 45 | 45 | 45 |
Total Shareholder's Equity | -35 | -26 | -20 | -35 | -39 |
Total Liabilities & Shareholder's Equity | 23 | 31 | 31 | 39 | 50 |
Total Common Equity | -35 | -26 | -20 | -35 | -39 |
Shares Outstanding | 22.05 | 21.66 | 14.50 | 14.30 | 14.30 |
Book Value Per Share | -1.58 | -1.19 | -1.37 | -2.45 | -2.70 |